|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-4-7
|
|
pubmed:abstractText |
The drug development process can be streamlined by combining the traditionally separate stages of dose-finding (Phase IIb) and confirmation of efficacy and safety (Phase III) using an adaptive seamless design. This approach was used in a clinical study of indacaterol, a novel once-daily (od) inhaled long-acting beta(2)-adrenoreceptor agonist bronchodilator for the treatment of COPD (chronic obstructive pulmonary disease).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1522-9629
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
165-71
|
|
pubmed:meshHeading |
pubmed-meshheading:20080201-Adult,
pubmed-meshheading:20080201-Bronchodilator Agents,
pubmed-meshheading:20080201-Dose-Response Relationship, Drug,
pubmed-meshheading:20080201-Double-Blind Method,
pubmed-meshheading:20080201-Ethanolamines,
pubmed-meshheading:20080201-Female,
pubmed-meshheading:20080201-Humans,
pubmed-meshheading:20080201-Indans,
pubmed-meshheading:20080201-Male,
pubmed-meshheading:20080201-Middle Aged,
pubmed-meshheading:20080201-Pulmonary Disease, Chronic Obstructive,
pubmed-meshheading:20080201-Quinolones,
pubmed-meshheading:20080201-Research Design,
pubmed-meshheading:20080201-Respiratory Function Tests,
pubmed-meshheading:20080201-Scopolamine Derivatives,
pubmed-meshheading:20080201-Severity of Illness Index
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.
|
|
pubmed:affiliation |
Imperial College, London, UK. p.j.barnes@imperial.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Clinical Trial, Phase II,
Clinical Trial, Phase III
|
